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Abstract: Background: Diets have been a central component of lifestyle modification for decades. The
Low-Carbohydrate Diet (LCD), originally conceived as a treatment strategy for intractable epilepsy
(due to its association with ketogenesis), became popular in the 1970s and since then has risen to
prominence as a weight loss strategy. Objective: To explore the efficacy, limitations and potential
safety concerns of the LCD. Data Sources: We performed a narrative review, based on relevant articles
written in English from a Pubmed search, using the terms ‘low carbohydrate diet and metabolic
health’. Results: Evidence supports the efficacy of the LCD in the short-term (up to 6-months) for
reduction in fat mass and remission of Type 2 Diabetes Mellitus (T2D). However, the longer-term
efficacy of the LCD is disappointing, with diminishment of weight loss potential and metabolic
benefits of the LCD beyond 6-months of its adoption. Furthermore, practical limitations of the LCD
include the associated restriction of food choices that restrict the acceptability of the LCD for the
individual, particularly over the longer term. There are also safety concerns of the LCD that stem
from nutritional imbalances (with a relative excess of dietary fat and protein intake with associated
dyslipidaemia and increased risk of insulin resistance and T2D development) and ketotic effects.
Finally, the LCD often results in a reduction in dietary fibre intake, with potentially serious adverse
consequences for overall health and the gut microbiota. Conclusions: Although widely adopted, the
LCD usually has short-lived metabolic benefits, with limited efficacy and practicality over the longer
term. Dietary modification needs tailoring to the individual, with careful a priori assessments of food
preferences to ensure acceptability and adherence over the longer term, with avoidance of dietary
imbalances and optimization of dietary fibre intake (primarily from plant-based fruit and vegetables),
and with a posteriori assessments of the highly individual responses to the LCD. Finally, we need to
change our view of diets from simply an excipient for weight loss to an essential component of a
healthy lifestyle.
Keywords: Low-Carbohydrate Diet; Type 2 Diabetes Mellitus; fat mass; ketogenesis
1. Introduction
The global obesity epidemic poses a major threat to our health, with much asso-
ciated chronic ill health that includes >50 separate obesity-related co-morbidities [1,2].
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Cardio-metabolic dysfunction underlies many obesity-related conditions, including Type 2
Diabetes Mellitus (T2D), other features of the metabolic syndrome such as dyslipidaemia
and hypertension and obesity-related malignancies that include endometrial carcinoma [3].
Global obesity also contributes to substantial socio-economic costs [4]. There is an urgent
need to address global obesity through efficacious and long-term strategies and preven-
tive measures.
Traditionally, there is division of obesity management into three distinct phases:
lifestyle, pharmacotherapy and bariatric surgery. Currently, bariatric surgery provides our
best evidence for long-term effective weight loss in obesity [5]. Although pharmacothera-
pies for obesity have a chequered history, there is much promise for the future based on data
from some of the newer classes of therapies for T2D, including incretin-based hormonal
suppressants of hunger [6,7]. Regarding lifestyle strategies for obesity, although usually
considered as an early strategy for weight loss, healthy lifestyle behaviours should form a
foundation for weight loss, applicable throughout its management and complementary to
other strategies.
Lifestyle is an umbrella term that incorporates all aspects of healthy behaviours includ-
ing sleep quality and sufficiency, physical activity, smoking cessation and the optimization
of mental and emotional health. Attention to diet forms a major component of a healthy
lifestyle. There are a myriad of diets available, based on multiple variables. These in-
clude the combinations of macronutrients, the duration and timing of meals, the duration
and periodicity of fasting periods, chewing time, the speed of eating, the duration of the
diet, the types of cooking techniques and even the emulation of previous eras such as
the ‘Paleolithic Diet’. Amongst all available diets though, the Low-Carbohydrate Diet
(LCD) features prominently. The LCD, conceived a century ago as a means of inducing
ketonaemia as a treatment strategy for intractable epilepsy [8], has only been re-purposed
for weight loss and metabolic benefits for the second half of its history, in response to the
burgeoning global obesity problem. Indeed, even prior to the discovery of insulin 100-years
ago, and before the conception of the LCD as a treatment for intractable epilepsy, severe
restriction of carbohydrate intake was advocated for the treatment of Type 1 Diabetes
Mellitus (T1D) [9]. In this concise review, we consider the definition, rationale and patient
selection for the LCD. We also critically review current literature on the metabolic efficacy
of the LCD, and consider its limitations and potential safety concerns. Finally, we outline
the role of the LCD in the context of a healthy lifestyle program and the future of the LCD.
2. Methodology
We performed a narrative review of the current literature. We used Pubmed for this
purpose. The search terms included ‘Low carbohydrate diet’ in combination with the
following: ‘metabolic health, definition, physical activity, limitations, nutrition, ketosis,
hyperuricaemia, inflammation and microbiota’. We chose published studies for inclusion
in our narrative review based on their relative size, novelty and perceived clinical relevance
as assessed by the authors; and related review articles, including systematic reviews and
meta-analyses. We only considered articles written in English, with no restrictions on the
date of publication.
3. Low-Carbohydrate Diet: Definition, Rationale and Patient Selection
The definition of the LCD varies between studies, and includes a diet that contains
<130 g of carbohydrate per day (or <26% carbohydrate from a 2000 Kcal/day diet) [10].
However, perhaps the most widely used definition of the LCD is based on the percentage of
total daily calories (<20%) derived from carbohydrates, with a relatively high proportion of
daily caloric intake from fats (55–65%) and protein (25–30%) [11]. The dietary composition
of the LCD differs markedly from the Low-Fat Diet (LFD) in which only 20–30% of total
daily calories stem from dietary fats, with 55–65% of daily calories derived from carbo-
hydrates and 15–20% derived from protein [11]. These definitions of the LCD and LFD
highlight a key underlying problem inherent to any study on dietary modification: the im-
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possibility of exploring the effects of macronutrient changes in isolation. Our diets contain
a complex array of macronutrients. If there is a reduced intake of one macronutrient (such
as carbohydrates), then there must be a relative increase in the daily caloric contribution
from other macronutrients (such as fats and protein), to compensate for the reduction in
carbohydrate intake. Therefore, it is important to emphasize that many dietary interven-
tions, including the LCD, are actually more complicated than their titles otherwise suggest.
This awareness is important when assessing the outcomes of diets such as the LCD.
Restriction of dietary carbohydrate intake has a long history, including as a treatment
strategy for T1D prior to the discovery of insulin [9]. Indeed, in 1863, Edward Banting
commented on his own personal experience of using dietary carbohydrate restriction
for weight loss (from 202 to 156 pounds): “the great charms of the system are that you are
never hungry and its effects are palpable within a week of trial and creates a natural stimulus to
persevere a few weeks more”. The original LCD (with relatively high dietary intakes of fat
and protein) was conceived 100 years ago in 1921 as a means of inducing ketogenesis, as a
non-pharmacological treatment option for intractable childhood epilepsy [8,12]. In recent
years, variations of this low-carb ‘ketogenic’ diet (defined as ketosis in the context of the
LCD) have improved its palatability and tolerability, and thereby widened its availability
to a larger group of patients, including adults who have failed to respond to multiple anti-
convulsant therapies and who are not surgical candidates [12]. Interestingly, despite its use
as a therapeutic option for intractable epilepsy for a century, the underlying mechanism(s)
whereby the low-carb ketogenic diet improves health outcomes in people with epilepsy
remains unclear [12]. Hypotheses include effects on mitochondrial function, changes in
neurotransmitter release and neuronal function that stem from the effects of ketone bodies
(including enhanced membrane potential hyperpolarization, increased γ-aminobutyric
acid [GABA] synthesis and reduced release of glutamate), and the anticonvulsant effects of
glucose stabilization and fatty acids [12]. The low-carb ‘ketogenic’ diet may also inhibit the
mammalian target of rapamycin (mTOR) [12–14]. For the first half of its history, the use of
the low-carb ‘ketogenic’ diet was mainly for the purpose of managing intractable epilepsy.
With the burgeoning global problem of obesity in the 1970s, there was a re-purposing
of the LCD for a very different indication: that of weight loss. The concept of the LCD
(associated with relatively high intake of protein and fats) for the purpose of weight loss
and weight maintenance was popularized in the 1970s by Dr. Robert C Atkins [15]. Since
then, and over the second half of its history, the LCD as a lifestyle strategy for weight loss
has become prominent, and now far out-weighs its original purpose as a treatment option
for intractable epilepsy.
The rationale of the LCD as a weight loss strategy stems from the Carbohydrate-
Insulin Model (CIM) of obesity. This suggests that high-carbohydrate diets (including
refined sugar and starches) stimulate post-prandial hyperinsulinaemia that in turn pro-
motes the deposition of calories within fat cells, rather than the alternate fate of oxidation
within lean tissues, with consequent weight gain (including effects on increased hunger
and suppressed metabolic rate) [16]. Of all the many influences on insulin secretion, dietary
carbohydrate has the most potent effect, and varies according to the amount and type
of carbohydrate [16]. Although protein also stimulates insulin secretion, there is tem-
pering of the effects of protein-induced hyperinsulinaemia by the concomitant secretion
of glucagon. Conversely, dietary fat has little direct effect on the release of insulin [16].
Following adoption of the LCD, two key metabolic processes ensue: gluconeogenesis and
ketogenesis [17]. A diminished supply of glucose to the muscles, brain and liver results
in a reduction in the synthesis and storage of glycogen, and therefore a reduced capacity
for glycolysis. Due to the reciprocal and inverse relationship between glycolysis and glu-
coneogenesis, diminishment of the former results in augmentation of the latter [17]. The
process of gluconeogenesis utilizes certain amino acids (alanine and glutamine), glycerol
and lactic acid as substrates [18]. Given the limited supply of these substrates, continuous
gluconeogenesis over a prolonged period of many hours may be insufficient to provide the
body’s needs for glucose. In this scenario, ketogenesis occurs with the synthesis of ketone
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bodies as an alternate fuel source to glucose [17]. Low levels of serum insulin that associate
with the LCD result in lipolysis with an elevated supply of fatty acids, with conversion to
acetoacetic acid and the ketones β-hydroxybutyric acid and acetone [17]. Based on these
physiological insights, adoption of the LCD would reduce levels of plasma insulin, and
promote the oxidation of ingested calories within lean tissues, with reduced storage as fat
and favourable effects on appetite and metabolic rate.
To appreciate further the metabolic benefits of the LCD, it is instructive to consider the
metabolic sequelae of adopting a high carbohydrate diet (HCD) that results in increased
insulin secretion, that in turn partitions energy away from oxidation and towards storage
depots such as fat deposition within adipose tissue [17]. In response to the brain’s per-
ception of ‘cellular internal starvation’, there is enhancement of appetite and suppression
of metabolic rate [17]. However, an alternate explanation for weight gain with a HCD
simply invokes the pleasant taste of sweetness and its inherent hedonic effects that in turn
drives us to eat more. The underlying mechanisms that link the HCD with resultant weight
gain may implicate appetite control, the hedonic centres, metabolic rate, insulin-mediated
energy partitioning or a combination of all of these factors. Whatever the actual mecha-
nisms, the literature provides clear consensus on the metabolic effects of diets according to
carbohydrate content: HCDs promote weight gain and metabolic dysfunction, and LCDs
promote weight loss (at least in the short-term) and optimization of metabolic functioning.
To summarize this section, the LCD is defined as a diet that has a low proportion of
daily calories (<20%) derived from carbohydrates. LCDs therefore also contain a relatively
high proportion of calories derived from dietary fat and protein, which hampers any
attempt to explore the effects of low dietary carbohydrate ingestion in isolation. Although
originally conceived as a treatment for intractable epilepsy, the primary application of
the LCD currently is to facilitate weight loss and metabolic improvements in people with
obesity, including obesity-related co-morbidities such as T2D. In this review, we focus on
the metabolic effects of the LCD in these scenarios. Ultimately, there is individualization of
the implementation of dietary interventions such as the LCD, according to their rationale
and purpose. It is important to consider carefully the available evidence when choosing
appropriate dietary interventions such as the LCD, including metabolic efficacy and safety.
4. Metabolic Efficacy of the LCD
Adoption of the LCD results in a reduced supply of carbohydrates to the liver that in
turn causes a reduction in the conversion of excessive carbohydrates into fatty acids and
enhanced lipolysis. There is also a reduction in the levels of plasma insulin that releases
the drive to store fat within adipose tissue, that ultimately manifests in progressive loss
of body fat [17]. Accordingly, reduced fat mass represents a key metabolic benefit and
rationale for the adoption of the LCD. Indeed, at least over the short-term, the LCD appears
to result in some superior reduction in body fat mass. The effects of the LCD and Very
Low-Carbohydrate Diet (VLCD) on body composition was reported based on a meta-
analysis of 14 randomized controlled trials (RCTs) that included >1400 obese individuals,
in which there was an overall greater reduction in fat mass of 0.77 Kg when compared to
the LFD [19]. In the sub-group with LCD over 12-months, the additional reduction in fat
mass was 0.57 Kg [19].
Despite these promising data on improved fat mass for the short-term efficacy of
the LCD, longer-term data are disappointing. Other meta-analyses based on longer-term
randomized weight loss trials that compare LCD with traditional calorie-restricted (low-fat)
diets show that although LCDs associate with greater weight loss in the short-term, this
advantage of the LCD either disappears or diminishes after 1 year [20–23]. The reduced
efficacy of the LCD on weight loss over the longer-term suggests the emergence of some
mitigating compensatory mechanism [24]. One hypothesis is that the reduced glycogen
stores that associate with the adoption of the LCD [25] result in reduced physical activity
and increased fatigue [24], with consequent reduced energy expenditure. However, no
consistent evidence from human-based studies supports any assumption that dietary
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composition and quality has an appreciable impact on physical activity, performance or
endurance in people adopting dietary modification (including the LCD) for the purpose
of weight loss [26–28]. There is also controversy regarding the effects of the LCD on the
capacity for physical activity in sportsmen [29–31]. In one fascinating study on Drosophila
melanogaster that compared a standard diet and LCD for 9-days, although activity was
unaffected by the diet, there was a relative reduction in overall metabolic rate in the LCD
group. Although caution is required when extrapolating data from Drosophila into humans,
suppressed overall metabolic rate may represent one possible factor that mitigates the
longer-term success of the LCD for effective reduction in body fat [24].
The potential metabolic benefits of the LCD extend well beyond reduced fat mass,
including for example potential improvement in the future risk of cardio-vascular disease
in patients with pre-diabetes and T2D [32,33]. Through a combination of reduced supply
of carbohydrates to the liver and suppressed plasma levels of insulin, the LCD associates
with improved (pre-prandial) insulin sensitivity and glycaemic control. Overall, fasting
insulin sensitivity improves over the short-term in response to the LCD, but the effect of
the LCD on fasting insulin sensitivity diminishes over the longer-term, in tandem with
the diminished longer-term effects on body weight loss [32,33]. (Unfortunately, limited
data exist for the effects of the LCD on post-prandial insulin sensitivity). In a systematic
review and meta-analysis of RCTs on the efficacy of the LCD versus a normal or high-
carbohydrate diet in patients with T2D from 9 studies and >700 individuals, there was
a significant reduction in HbA1C of 0.44% for the LCD group [34]. The LCD group also
had a significant reduction in plasma triglyceride level of 0.33 mmol/L but no significant
change in total or LDL cholesterol. Furthermore, although the LCD had an initial reducing
effect on body weight, over the longer term (as with outcomes from the general obese
cohorts outlined above), there was no significant effect of the LCD on body weight [34].
In a separate study on adoption of the LCD in obese patients with T2D, there was a
short-term improvement in insulin sensitivity, optimization of glycaemic control and lipid
profile, a spontaneous reduction in energy intake and weight loss (accounted for by the
reduced caloric intake) [35]. Furthermore, in a recent meta-analysis of the LCD in patients
with T2D on >1350 participants, it was demonstrated that compared with control diets at
6-months, the LCD achieved higher rates of remission from T2D (data on T2D remission
at 12-months were sparse), and improvements in weight loss, fasting insulin sensitivity
and triglycerides that diminished at 12-months [10]. Finally, the effects of the LCD on non-
alcoholic fatty liver disease (NAFLD) remains incompletely understood. Although human
data show association of the LCD with a reduction in intra-hepatic triglyceride content,
longer-term maintenance of a ketogenic diet in mice actually stimulates the development
of NAFLD [36].
Despite the clear metabolic benefits of the LCD for patients with T2D at least in the
short-term, there remains controversy in the literature regarding the relative benefits of
the LCD versus other dietary modifications in T2D. In one systematic review and meta-
analysis that compared the metabolic effects of the LCD vs. HCD in adults with T2D, the
proportion of daily energy provided by carbohydrate intake was not an important factor in
the response to dietary management [37]. Furthermore, in a recent meta-analysis, there
was an inverse association between T2D incidence and increased intake of whole-grain,
and a direct association with the intake of sugar-sweetened beverages [38]. There is also
contention regarding the origin of the metabolic benefits of the LCD, with potential benefits
from the diet itself, and the indirect metabolic effects that stem from reduced hunger and
associated weight loss [39]. It seems likely that a combination of these factors underlies the
metabolic benefits of the LCD (at least in the short-term), an overview of which we present
in Figure 1.
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lt t adoption of the LCD seems a sensible lifestyle approach, and one cor-
r borated by scientific evid nce for the short-term p omotion f weight loss and improved
metabolic status, it is important n t to overlo k the p tential benefits of other types of
dietary modification for effective weight loss and metabolic improvements. In on meta-
a alysis of 32 controlled feeding studies in diet-induced obese mice in which there was
isocaloric substitution of carb hydrate f r fat, both energy exp ditur and loss of fat
mass were significantly greater with lower fat diets [40]. Although we should exercise
caution when extrapolating r de t data to humans, the LFD in huma s also a sociates
with effective w ight loss [11]. Furthermore, there are pot ntial practical problems and
safety concerns that limit e effec ive and longer-term adoption of the LCD, explored
in the next sub-sections. Therefore, it is important not to choose the LCD by default,
but rather consider dietary and lifestyle options from a holistic perspective, tailored to
each individual.
5. Limitations of the LCD
Any successful behavioural change requires sustained focus, drive, grit and determi-
nation. Although habitualization is possible, behavioural change over the longer term is
often challenging. All of us experience life events that demand our focus and attention
and may dominate our emotions temporarily. It is at such moments that maintained focus
on healthy behaviours including dietary modification becomes particularly challenging,
and where many of us falter. The longer-term adherence to diets such as the LCD is no
exception. Indeed, poor adherence to dietary recommendations is a major reason for the
limited efficacy of dieting per se [41]. The longer-term success of any dietary modification
depends on its acceptability to the individual and influenced by its practical applicability
and, importantly, the enjoyment associated with its adoption. Unfortunately, much of
the pleasurable hedonic effects of eating stem from the ingestion of carbohydrate, and
particularly the combination of carbohydrates and fat (that never occurs naturally). Sweet
foods are palatable. This poses a problem for the LCD, with potentially reduced palatability
of foods that are low in carbohydrates and associated reduced enjoyment from eating con-
tributing to the longer-term problem of adherence to the LCD. Furthermore, the successful
adoption of the LCD often results in severe limitation of food choices, with the attendant
risk of inadequate nutrition. This further hampers sustained adherence to the LCD [11].
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The achievement and maintenance of a healthy body weight is unlikely to occur
unless the lifestyle opted for (including dietary modification and physical exercise) are
enjoyable [42]. Given individual preferences for food, it follows that the choice of diet
should be tailored to the individual [42]. There should be encouragement of changes to
the diet that are acceptable to the individual and that can be maintained [42]. Attempts to
follow a specific diet that is unacceptable or unpleasant for an individual is unlikely to be
successful, and may actually be de-motivating and have a negative impact on self-esteem,
self-confidence and likelihood of engagement with other healthy lifestyle behaviours.
Therefore, prior to advocating any diet, a carefully elicited dietary history is required,
including the types of foods and recipes that the individual finds acceptable and enjoyable.
In some cases, a modified LCD may be required, that maintains some elements of the
LCD, but may be tempered to improve its acceptability to the individual and therefore to
optimize the likelihood of its longer-term success.
In addition to the acceptability and palatability of the LCD, a further potential limita-
tion relates to its possible hampering of athletic performance. In one study on the effects of
the LCD (with associated high-fat diet [HFD]) in elite endurance athletes, in contrast to
diets that provide high-carbohydrate availability, training with the LCD impaired athletic
performance despite improved peak aerobic capacity [30]. However, as alluded to earlier,
there is relatively little evidence from the literature to support any appreciable effects of the
LCD on physical endurance and performance for most people who adopt this diet. Further-
more, elite athletes should not represent a standard model from which to judge the physical
effects of the LCD in most people who adopt it. Nevertheless, when choosing an appropriate
diet, it is important to consider not just its metabolic effects and weight loss potential, but
also the potential impact on physical activity, and occasionally and where relevant, athletic
performance. Although optimized athletic performance may not be a priority for many of
us, the data outlined here nonetheless highlight the importance of a tailored approach to the
individual, including consideration for the minority with a focus on athleticism.
6. Potential Safety Concerns of the LCD
The longer-term metabolic and weight-losing efficacy of the LCD, its acceptability
to the individual and associated limitations are important considerations. However, an
even greater concern relates to the potential safety concerns of the LCD that originate from
multiple sources (outlined in Table 1).
Nutritional Deficiencies: In patients with Type 1 Diabetes Mellitus, adoption of the
LCD may result in an increased risk of severe hypoglycaemia, that is resistant to the effects
of glucagon due to the associated depletion of glycogen stores [43]. Apart from glycogen
deficiency, other nutritional deficiencies associated with the LCD stem from restrictions of
dietary choice (and therefore the risk of a nutritionally imbalanced diet), compounded by
a concomitant drive to lose weight with additional deliberate restriction of caloric intake.
Accordingly, the longer-term adoption of the LCD (usually following at least 3-months)
can result in dietary deficiencies of minerals, vitamins and trace elements and associated
problems with bone health, renal calculi and occasionally growth failure [12]. A relative
paucity of dietary fibre intake in the LCD (from the predominance of animal-based high fat
and high protein foods, and relative lack of plant-based foods that contain carbohydrates
in the form of dietary fibre) may cause constipation and other health problems [44]. Over
the longer term, these imbalances of macronutrient intake can have potentially deleterious
effects that stem from relatively high dietary intakes of fat (such as dyslipidaemia [12]) and
protein (such as impaired glomerular filtration rate demonstrated in women with mild
renal impairment, but not in healthy subjects with eGFR > 60 mL/min/1.73 m2 [11,45–47]).
Furthermore, diets that have both low and high percentages of carbohydrates associate
with increased mortality, with minimal mortality risk at 50–55% carbohydrate intake (with
a plant-based diet) [48]. A relative lack of plant-based foods (including vegetables and
legumes) in the LCD may worsen mortality from a reduced intake of essential micronutri-
ents such as polyunsaturated fatty acids (PUFA) [49,50].
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Ketosis: To complement the nutritional problems that associate with longer-term
adoption of the LCD, there are also potential safety concerns from the effects of persistent
and sustained ketosis. In the short-term, these include potential gastro-intestinal symptoms
such as vomiting, diarrhoea, obstipation, gastroesophageal reflux and hypoglycaemia [12].
The longer-term effects of sustained ketosis on the body are incompletely understood [11].
However, ketosis can result in released calcium stores to neutralize the ketones, with a
theoretical risk of osteoporosis and nephrolithiasis [11]. Interestingly, epidemiological data
reveal that higher protein intake actually associates with reduced bone loss [51]. In extreme
and rare cases, carbohydrate restriction may even precipitate ketoacidosis [52].
High-Protein Diet: The LCD associates with intake of a relatively high proportion of
dietary protein (to compensate for a relative lack of carbohydrate as a source of energy).
There is controversy in the literature regarding the health effects of a high-protein diet.
Over the longer term, there are reported unfavourable metabolic effects of a diet that is
proportionately high in protein, including association with dysglycaemia [53,54]. In a large
prospective cohort study with 1-year follow-up, consumption of energy from protein at
the expense of energy from fat or carbohydrates actually increased the risk for the devel-
opment of T2D [53,54]. Conversely, a recent guidelines publication by the Diabetes and
Nutrition Study Group (DNSG) justified higher protein diets (up to 20% and 1.3 g/Kg body
weight) for the treatment of T2D, providing normal renal function [47]. Interestingly, there
appears to be a contradiction between the epidemiological and interventional studies on
high-protein diets, with the latter (20–30% daily energy requirements from dietary protein
in the context of a healthy dietary intake of fats, fibres and vegetables) showing consistently
favourable metabolic outcomes and biomarkers. Such interventional data include the
ProFiMet study with the combination of a high-protein diet with fibre intake [55], and a
series of reported studies on the metabolic benefits of high-protein diets on improvements
in hepatic fat content, inflammatory profiles and oxidative stress, including in people with
T2D and obesity [56–59]. A likely explanation for the apparent disconnect between the
metabolic data from epidemiological and interventional studies on high-protein diets is that
the former often fail to correct for lifestyle variables associated with a high dietary protein
intake, with a relative lack of plant-based foods and physical inactivity. Conversely, inter-
ventional studies on high-protein diets (including those discussed here) usually combine
these with a healthy lifestyle program (including a healthy diet), with recent meta-analyses
that reveal improvements in most metabolic outcomes [60]. Therefore, based on current
evidence, high-protein diets per se do not appear to influence metabolic health, but rather
the healthiness of their associated diet and other lifestyle behaviours.
Hyperuricaemia and Inflammatory Effects: A further theoretical risk of the LCD
includes hyperuricaemia (with associated gouty arthritis and uric acid nephrolithiasis)
from excessive conversion of purines from animal proteins following adoption of the LCD
(with relatively high dietary intake of proteins) [11,61]. However, it is noteworthy that
purines also originate from plant-based foods that contain lots of DNA such as cabbage,
and that fructose represents an important source of uric acid formation [62]. Finally,
theoretically the LCD may promote inflammatory effects through a relative increase in
saturated fat intake (possibly mitigated through associated weight loss). In fact, evidence
suggests either no appreciable effects [63] or improvements in inflammatory status (at least
in the short term) from the LCD [64–67], and associated improvements in the risk factors
for cardiovascular disease [68]. Future longer-term prospective studies should explore the
longer-term effects of the LCD on cardio-vascular events.
Mitigation of some of the nutritional and metabolic problems associated with the
LCD could occur through the concomitant optimization of dietary fibre intake. Our own
group showed that the ingestion of insoluble and non-fermentable cereal fibres (derived
from oat or wheat extracts and whole grain products) rather than soluble and highly
fermentable types of dietary fibre, associates with reduced risk for the development of
T2D and improved insulin sensitivity [55,69,70]. We have proposed a likely mechanistic
explanation for the association between dietary fibre intake and improved insulin sensitivity
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to implicate the reduced absorption of dietary protein and modulation of the amino acid
metabolic signature [70,71]. The combination of the LCD with optimized dietary fibre
intake may therefore help to reduce the potential detrimental metabolic effects (including
insulin resistance) of excessive protein intake, and may reduce the risk of hyperuricaemia.
However, this strategy is problematic given that most carbohydrates occur within plant-
based foods (in the form of dietary fibre), and the LCD is therefore typically low in dietary
fibre. Dietary restriction of fermentable and poorly absorbed carbohydrates (as occurs in
the LCD) can have beneficial effects in patients with symptoms of Irritable Bowel Syndrome
and small intestinal bacterial overgrowth, in whom reversal of this dietary strategy may
therefore worsen such symptoms [72,73]. Furthermore, supplementation of the LCD with
fibre-rich foods may potentially exceed the daily limit of carbohydrates allowable for
the LCD. To address these problems, supplementation of the LCD with insoluble fibre-
rich foods such as cereal fibre (that tends to have a lower carbohydrate content than its
counterpart, soluble fibre) provides a potential solution, and would enable the adoption
of the LCD whilst also maintaining adequate dietary fibre intake [74–76]. Furthermore,
fibre-rich vegetables contain relatively low levels of carbohydrate, primarily soluble and
metabolically ineffective fibre and essential micronutrients (likely accounting for their
health benefits), and as such provide an excellent accompaniment to the LCD. Additional
strategies include fibre supplementation and fortification of the LCD.
Table 1. Outline of the potential safety concerns of the LCD.
Safety Concern Nature of the Problem Clinical Sequelae
Nutritional
Deficiencies
Reduced dietary intake of fibre, minerals,
vitamins, trace elements and PUFA [12];
Depleted glycogen stores from
restricted carbohydrate intake [43]
Increased mortality from restricted fibre,
essential micronutrients and PUFA [48–50];




symptoms [12]; Longer-term effects incompletely
understood [11]
Released Calcium Stores [11]
Vomiting, Diarrhoea and Obstipation;
Gastrointestinal reflux [12];
Theoretical Nephrolithiasis and
Osteoporosis [11]; Ketoacidosis (rare) [52]
High-Protein Diet
Epidemiological studies show association with
dysglycaemia and unfavourable metabolic effects
[53,54]; Interventional studies show metabolic
benefits [55–59]
Impaired GFR in women with mild renal
impairment [11,45–47]; Metabolic benefits likely
mediated by associated lifestyle changes in
interventional studies [60]





inflammatory effects from a relative increase in
dietary saturated fat intake
Evidence is contradictory
Data show either no appreciable effect [63] or
improvement of inflammatory
status [64–67] in response to the LCD
Mental and Emotional
Status
Central role of food and eating
within our society
Potential lowering of mood and
negative impact on relationships
Ecological and Ethical
Concerns
Environmental effects of soy bean and meat
production and deforestation Health implications of climate change
Financial Implications
Increased expense of the LCD [77], and
disproportionate financial effects on lower
socio-economic groups
(reduced affordability and feasibility)
Health implications of financially
restricted diet to those groups most likely to
benefit from dietary change
Dysbiosis
Relative increase in dietary intake of fats and
protein, with a deficiency
in dietary fibre intake [78]
Appetitive, immunomodulatory,
inflammatory and dysmetabolic
sequelae; Impact on mental health and
wellbeing [79]
GFR: Glomerular Filtration Rate; LCD: Low-Carbohydrate Diet; PUFA: Polyunsaturated Fatty Acids; T1D: Type 1 Diabetes Mellitus.
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As outlined, the main safety concerns regarding adoption of the LCD relate to their
nutritional and ketotic effects. Furthermore, epidemiological studies consistently report
increased mortality with the LCD [48]. Whilst the direct effects of the LCD are important,
there are also potential indirect safety concerns. As outlined earlier, adoption of the LCD
inevitably results in a diminishment of glycogen supplies that may in turn contribute
towards fatigue, and reduced athletic performance [30]. Furthermore, given the restricted
food choices, potentially reduced pleasure of eating and the fact that the LCD is often
adopted in the context of obesity (a highly stigmatized condition in our society), it is
important to consider the potential mental and emotional health problems that may occur
following adoption of the LCD. Adoption of the LCD may also have a negative impact on
relationships, given the central role of food and eating in our social world. As healthcare
professionals, we need to be mindful of these issues, and consider the mental health and
social scaffold of our patients both prior to suggesting any dietary modification, and at each
follow-up opportunity whilst on any diet, including the LCD. There are also ecological and
ethical implications of promoting and adopting the LCD for many patients, including the
environmental effects of soy and meat production, deforestation and consequent effects on
climate change. The socio-economic implications of the LCD include the increased financial
expense of the LCD compared with other diets [77], that may preclude the feasibility and
affordability of the LCD for lower socio-economic groups within society (who are also most
likely to benefit from lifestyle and dietary changes).
Finally, although this goes well beyond the scope of our concise review, we need to con-
sider the potential for the indirect effects of gut dysbiosis that may stem from adoption of
the LCD, with the inherent high intake of fats and protein, typically found in animal-based
foods, and relative paucity of carbohydrate- and fibre-laden plant-based foods [78]. Given
the emergent data that link our gut microbiota with much of our physiological functioning
including the regulation of appetite, metabolism and mental health and wellbeing [79], it is
important to consider the impact of any dietary modification on our gut microbiota. This
consideration has perhaps, not been given enough attention previously, with too much
focus on weight loss per se following implementation of the LCD.
7. Conclusions and Future Directions: LCD in the Context of Healthy Lifestyle
Despite decades of research, it is remarkable how little we actually know about the
human diet. It is probably fair to say that most of us think we know more than we actually
do. There are many reasons why dietary insights remain elusive. These include the inherent
difficulties of studying diets in isolation, with every diet containing a complex array of
macronutrients and many other variables. There is also the problem of accuracy, with most
of us under-estimating our daily caloric intake and problems of self-recall that plague many
dietary studies. There are cultural factors, with specific dietary preferences and norms
widely variable across global populations. Finally, there are human variables from our own
unique genetic and physiological make-up, and the complex array of microbiota within our
gut, unique to each individual. Faced with this complex and highly variable set of factors,
it is hardly surprising that we have limited knowledge and insights into the optimization
of our diets for health.
Although specific dietary advice exists for certain groups, the vast majority of us are
encouraged to follow the standardized government advice regarding a healthy diet, with
recommended daily caloric intakes simplified based on sex. However, a more refined
approach is required, one that is tailored to the individual, and based on much more
sophisticated inputs than sex. As alluded to, the gut microbiota is hugely relevant to our
handling of macronutrients, and a future scenario may incorporate individualized gut
faecal profiles that inform specific dietary requirements [80]. Genetic profiling may also
be included (including gene variants relevant for liver handling of macronutrients for
example). A sophisticated dietary algorithm may even incorporate a Bayesian process, in
which there is algorithmic learning over time regarding how each individual responds to
and assimilates certain diets and macronutrients across a whole range of measures. Such
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a tool would enable users to make individualized healthy and enjoyable food choices.
Algorithmic learning and tailored dietary recommendations would help to ensure the
longer-term success and durability of healthy dietary modifications.
Ultimately, our diet should form an essential component of a healthy lifestyle. From
a nutritional perspective, it is important that any dietary intervention contains a proper
balance of healthy fats, proteins, carbohydrates, fibre, minerals and vitamins [11]. Due
to the problem of longer-term adherence to dietary modifications, any dietary interven-
tion must also be flexible and fit with individual lifestyles, backgrounds, cultures and
food preferences [11]. Physical activity and sleep are also important [11]. Based on the
available evidence, it is clear that there are specific metabolic benefits (including, for exam-
ple improved glycaemic control) from the adoption of the LCD. However, these benefits
appear short-lived. Conversely, the longer-term benefits of the LCD are disappointing.
As a longer-term weight loss strategy, the LCD is simply ineffective in the majority of
individuals who adopt it, primarily due to difficulty in sustained adherence to dietary
interventions [11]. There are also potential safety concerns with the longer-term applica-
tion of the LCD, as outlined. Indeed, very few people are able to maintain weight loss
following the implementation of any lifestyle intervention, including long-term dietary
modifications [11].
How can we proceed in the future to optimize our diets for maximal health benefits?
There is clearly a need for more large-scale, prospective multi-centre trials on the effects of
the LCD. Despite the publication of >100 separate LCD and LFD randomized controlled
trials, our understanding of the benefits of the LCD remains limited, at least in part due
to heterogeneity amongst the design of different studies. We suggest a bold initiative to
explore major dietary approaches such as the LCD on the same scale as research in thera-
peutics, with a 1–5 year duration and inclusion of >5000 participants. Such a study design
would enable the exploration of major primary assumptions (such as remission/prevention
of T2D and CVD outcomes), and many secondary assumptions (such as compliance, sub-
group analyses [to ascertain the subgroups that are particularly responsive to the LCD and
predictors of response] and nutrigenetics). With antecedents of the PREDIMED (Prevención
con Dieta Mediterránea) study on the benefits of the Mediterranean diet [81] and the Look
AHEAD (Action for Health in Diabetes) study on the benefits of the LFD (as part of an
intensive lifestyle intervention) [82], the execution of a large-scale study on the LCD is
well overdue.
As outlined earlier, an individualized and algorithmized approach to diets seems
sensible. We also need to change our societal mind-set regarding the purpose of dietary
change. Rather than diets perceived simply as a means to lose weight, we need to change
our perspective to one in which diets are considered as an essential component of healthy
lifestyle, which if followed correctly with other lifestyle measures, will improve our future
health outlook, and may even optimize our body weight. Above all, for longer-term
adherence, it is essential that whatever the chosen lifestyle strategy (including dietary
change), this is practical, feasible and importantly enjoyable for the individual engaged
in such behaviour changes. Without enjoyment, any long-term change is destined to fail.
Perhaps one reason why dietary and lifestyle changes are so disappointing over the longer
term is that the available options are too rigid, and as healthcare professionals, we do not
invest enough time in ascertaining practicality, feasibility and enjoyability of suggested
behaviour changes for each individual prior to making such recommendations. With such
a priori assessments, we can tailor our approach to the individual, and any recommended
lifestyle change, dietary or otherwise, will have a greater chance of longer-term success.
In addition to rigidity, perhaps our traditional approach to diets is also too prescriptive.
The available evidence shows that weight loss occurs following a reduction in daily caloric
intake, regardless of the macronutrient origin of those calories, although the magnitude of
weight loss varies according to the type of macronutrient, and the effects on diet-induced
thermogenesis [11]. Therefore, rather than considering the merits of the LCD versus
LFD or any other macronutrient change, perhaps our approach should simply be to limit
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caloric intake, whilst maintaining a healthy and enjoyable diet, and nurturing our gut
microbiota with fibre and plant-based foods in the process. The magnitude of limitation in
caloric intake (isocaloric balanced diet versus caloric restriction) requires careful tailoring
to the individual, with occasional avoidance of caloric restriction, including in the sub-
group of patients with T2D and normal-weight and/or older age. (In elderly patients, the
adoption of the LCD may worsen the loss of subcutaneous adipose tissue, development
of sarcopenia and the risk of renal insufficiency). In the majority of patients with T2D,
however, caloric restriction represents an excellent treatment option. In the DIRECT trial
(Diabetes Remission Clinical Trial), caloric restriction to between 825 and 853 Kcal/day in
adult patients with T2D resulted in nearly 50% remission to a nondiabetic state at 12-months
and a mean weight loss of 10 Kg (with a minority achieving >15% body weight loss) [83].
Although the longer-term adherence to caloric restriction of this magnitude may prove
challenging to many, and it will be important to review carefully the longer-term follow-up
data from the DIRECT cohort, these initial data are indeed promising, and demonstrate
proof of concept that caloric restriction is a feasible option, at least in the short-term.
To conclude, evidence reveals metabolic efficacy of the LCD at least during the short-
term. Unfortunately, there are substantial limitations to the LCD that restrict its metabolic
efficacy over the longer-term, coupled with potential safety concerns. Compared with the
LCD, caloric restriction offers a greater selection of food (including plant- and fibre-based)
options with fewer safety concerns (provided maintenance of a balanced diet). Perhaps
even relatively modest caloric restriction provides a practical, feasible and enjoyable
dietary alternative to the LCD, accomplishable over the longer-term and offering hope for
the future.
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